ATLANTA – Elekta (EKTA-B.ST) today announced that its MOSAIQ® Oncology Information System (OIS) has earned the “Best in KLAS” designation in the 2024 Best in KLAS: Software and Services Report. MOSAIQ ranked first in the Oncology (Radiation) category. Based on feedback from thousands of providers, awards are based on evaluations collected by KLAS, an independent research firm.

A fixture in many of the world’s leading cancer care facilities, MOSAIQ is the multidisciplinary backbone of the company’s Elekta ONE™ unified software environment. Elekta ONE brings all Elekta software products, solutions and services under one umbrella and includes radiation therapy planning, comprehensive treatment management and delivery.

"In an era driven by AI, data, and software, we take pride in offering solutions that enable the providers we serve to elevate care for their patients," says Carlos Castilleja, Executive Vice President, Region Americas. “We remain steadfast in our commitment to be a trusted partner and adapt to our customers' evolving needs by providing unparalleled service and support across all of our products, including Elekta ONE.”

Anish Patankar, SVP and Head of Elekta’s Oncology Software Solutions Business Line adds: “The introduction of Elekta ONE, a software as a service (SaaS) offering, demonstrates our focus on personalization, integration and a streamlined user experience that makes it easy for our customers to boost productivity and focus on treating their patients. Winning this prestigious award, and the increased use of MOSAIQ globally, is the result of our software investment in recent years. We see how accelerating innovation is having a direct benefit to healthcare providers and those they treat.”

The 2024 report showed that MOSAIQ outperformed competitors in several categories. User feedback was measured across several areas, including culture, loyalty, operations, product, relationships, and value.

Elekta will receive the award on March 11 during the “Best in KLAS Awards Show” at HIMSS24 in Orlando.

For more information, visit: www.elekta.com/ONE.

*Elekta ONE is comprised of multiple Elekta solutions, some of which may not yet be available in all markets.

# # #

For further information, please contact:
Mattias Thorsson, Vice President, Head of Corporate Communications
Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com
Time zone: CET: Central European Time

Raven Canzeri, Global Director, Media Relations
Tel: +1 770-670-2524, e-mail: Raven.Canzeri@elekta.com
Time zone: ET: Eastern Time

About Elekta
As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,500 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com or follow @Elekta on X (formerly Twitter).